Table 1.
Baseline Characteristics of the Study Population With Inflammatory Bowel Diseases
| Characteristics | Total cohort (n = 141) | CD (n = 79) | UC (n = 62) |
|---|---|---|---|
|
| |||
| Female gender, n (%) | 79 (56.0) | 49 (62.0) | 30 (48.4) |
| Age, y, mean (SD) | 40.19 (16.9) | 38.71 (14.8) | 42.08 (19.1) |
| Hispanic ethnicity, n (%) | 6 (4.3) | 2 (2.5) | 4 (6.5) |
| Race, n (%) | 0.12 | ||
| White | 129 (91.5) | 69 (87.3) | NA |
| African American | 10 (7.1) | 8 (10.1) | NA |
| Asian | 2 (1.4) | 2 (2.5) | NA |
| Other | 0 (0) | 0 (0) | NA |
| Active smoker, n (%) | 14 (9.9) | 13 (16.5) | 1 (1.6) |
| Age of diagnosis, n (%) | |||
| Younger than 40 y | 99 (70.2) | 56 (70.9) | 43 (69.4) |
| 40 y or older | 42 (29.8) | 23 (29.1) | 19 (30.7) |
| Years with IBD, median (IQR) | 6 (2–13) | 8 (2–14) | 5 (1–10) |
| History of bowel resection, n (%) | 20 (14.18) | 20 (25.32) | 0 (0) |
| No. of bowel resections (if any), n (%) | |||
| 1 | 11 (5) | 11 (55) | 0 (0) |
| 2 | 5 (25) | 5 (25) | 0 (0) |
| 3 | 2 (10) | 2(10) | 0 (0) |
| 4 | 1 (5) | 1 (5) | 0 (0) |
| Unknown (≥1)a | 1 (5) | 1 (5) | 0 (0) |
| Phenotype of CD | |||
| Location, n (%) | |||
| L1: Ileal | 19 (24.1) | 19 (24.1) | NA |
| L2: Colonic | 14 (17.7) | 14 (17.7) | NA |
| L3: Ileocolonic | 46 (58.2) | 46 (58.2) | NA |
| L4: Upper gastrointestinal tract involvement, n (%) | 6 (7.6) | 6 (7.6) | NA |
| Peri-anal disease, n (%) | 3 (3.8) | 3 (3.8) | NA |
| B1: Not stricturing, nonpenetrating, n (%) | 32 (40.5) | 32 (40.5) | NA |
| B2: Stricturing, n (%) | 30 (38.0) | 30 (38.0) | NA |
| B3: Penetrating, n (%) | NA | ||
| Yes | 17 (21.5) | 17 (21.5) | NA |
| No | 62 (78.5) | 62 (78.5) | NA |
| Phenotype of UC | |||
| UC extension, n (%) | |||
| Proctitis | 2 (3.2) | NA | 2 (3.2) |
| Left-sided colitis | 18 (29.0) | NA | 18 (29.0) |
| Pan-colitis | 42 (67.7) | NA | 42 (67.7) |
| Baseline body composition parameters | |||
| Total mass, kg, mean (SD) | 81.61 (20.9) | 82.15 (22.4) | 80.93 (18.9) |
| Body mass index, kg/m2, mean (SD) | 28.29 (6.9) | 28.74 (7.6) | 27.70 (5.8) |
| Percentage of body fat, mean (SD) | 35.01 (10.5) | 35.80 (10.4) | 34.00 (10.6) |
| Total IA-VAT mass, kg, mean (SD) | 1.20 (1.1) | 1.24 (1.1) | 1.15 (1.1) |
| Total fat mass, kg, mean (SD) | 29.64 (14.4) | 30.67 (15.5) | 28.31 (12.9) |
| IA-VAT percentage of total body mass, mean (SD) | 1.32 (0.98) | 1.36 (0.98) | 1.27 (0.99) |
| Total lean mass, kg, mean (SD) | 48.51 (10.9) | 48.04 (10.4) | 49.12 (11.5) |
| Medications at baseline and previous exposure | |||
| Previous use of biologics, n (%) | 87 (61.7) | 54 (68.4) | 33 (53.2) |
| No. of previous biologics, n (%) | |||
| 1 | 34 (39.1) | 18 (33.3) | 16 (48.5) |
| 2 | 30 (34.5) | 20 (37.0) | 10 (30.3) |
| 3 | 15 (17.2) | 10 (18.5) | 5 (15.2) |
| 5 | 2 (2.3) | 2 (3.7) | 0 (0) |
| Unknown (≥1)b | 6 (6.9) | 4 (7.4) | 2 (6.1) |
| Biologic started, n (%) | |||
| Infliximab | 52 (36.9) | 33 (41.8) | 19 (30.7) |
| Ustekinumab | 43 (30.5) | 33 (41.8) | 10 (16.1) |
| Vedolizumab | 46 (32.6) | 13 (16.5) | 33 (53.2) |
| Steroids at baseline, n (%) | |||
| Budesonide | 37 (26.2) | 29 (36.7) | 8 (12.9) |
| Prednisone | 57 (40.4) | 23 (29.1) | 34 (54.8) |
| None | 47 (33.3) | 27 (34.2) | 20 (32.3) |
| Dose of budesonide,c n (%) | |||
| 6 mg | 4 (10.8) | 4 (13.8) | 0 (0) |
| 9 mg | 33 (89.2) | 25 (86.2) | 8 (100) |
| Dose of prednisone,c mg, mean (SD) | 31.93 (10.4) | 29.57 (11.4) | 33.53 (9.5) |
| Months the patient had been on steroids,c median (IQR) | 1 (1–2) | 1 (1–2) | 1 (1–2) |
| Use of mesalamine, n (%) | 13 (9.2) | 3 (3.8) | 10 (16.1) |
| Receiving combination therapy with immunomodulator, n (%) | 63 (44.7) | 41 (51.9) | 22 (35.5) |
| Receiving a thiopurine for combination therapy, n (%) | 51 (36.2) | 32 (40.5) | 19 (30.7) |
| Dose of thiopurine,c mg, mean (SD) | 101.0 (49.5) | 96.9 (42.0) | 107.9 (60.7) |
| Receiving a methotrexate for combination therapy, n (%) | 15 (10.6) | 12 (15.1) | 3 (4.8) |
| Dose of methotrexate,c n (%) | |||
| 12.5 mg | 13 (86.7) | 10 (83.3) | 3 (100) |
| 15 mg | 2 (13.3) | 2 (16.7) | 0 (0) |
| Baseline disease activity | |||
| Simple Endoscopic Score for CD,d median (IQR) | 9 (7–15) | 9 (7–15) | NA |
| Harvey Bradshaw Index,d median (IQR) | 5 (3–8) | 5 (3–8) | NA |
| Partial Mayo Score,e median (IQR) | 5 (4–6) | NA | 5 (4–6) |
| EMS,e n (%) | |||
| 2 | 36 (58.1) | NA | 36 (58.1) |
| 3 | 26 (41.9) | NA | 26 (41.9) |
| C-reactive protein, mg/dL, median (IQR) | 0.5 (0.25–1.3) | 0.5 (0.3–1.6) | 0.34 (0.2–1.0) |
| Albumin, mg/dL, mean (SD) | 4.17 (0.5) | 4.19 (0.5) | 4.15 (0.5) |
| Fecal calprotectin,f μg/mg, median (IQR) | 675 (285–1250) | 485 (182–1373) | 829 (323–1250) |
| Simple Inflammatory Bowel Disease Questionnaire, mean (SD) | 47.96 (11.1) | 46.95 (12.0) | 49.26 (9.7) |
IQR, interquartile range; NA, not applicable.
a
Patients with a history of resection but unknown number.
b
Patients with previous exposure to at least 1 biologic, but unknown how many.
c
As applicable.
d
Patients with CD.
e
Patients with UC.
f
70 patients in the cohort had baseline fecal calprotectin performed.